{
  "id": 18113015,
  "title": "Marksans Pharma Q2 Profit Soars 45% To ₹143.5 Crore, Revenue Crosses ₹900 Crore For First Time As Global Business Shines",
  "url": "https://urgent.news/2026/11/04/marksans-pharma-q2-profit-soars-45-to-143-5-crore-revenue-crosses-900",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-04T11:11:27.000Z",
  "source": {
    "name": "Free Press Journal",
    "slug": "free-press-journal",
    "url": "https://www.freepressjournal.in/business/marksans-pharma-q2-profit-soars-45-to-1435-crore-revenue-crosses-900-crore-for-first-time-as-global-business-shines"
  },
  "original_language": "en",
  "account": "Mumbai-based pharmaceutical company Marksans Pharma reported a remarkable surge in its second quarter earnings of FY27, with net profit soaring by 44.8 percent to ₹143.5 crore, marking a notable increase from ₹99.1 crore in the same period last year. Operating revenue also marked a substantial rise of 30.5 percent to ₹940.2 crore, surpassing the ₹900 crore threshold for the first time.\n\nThe company's earnings before interest, tax, depreciation, and amortisation (EBITDA) experienced a significant jump of 48.3 percent, soaring to ₹214.3 crore during the July-September quarter, compared to ₹144.5 crore a year earlier. This surge in EBITDA margin reached 22.8 percent, indicating enhanced operating profitability alongside the rise in revenue.\n\nFor the first half of FY27, Marksans Pharma's operating revenue reached ₹1,781 crore, and the net profit stood at ₹302.9 crore. European markets, particularly the UK and Europe, emerged as pivotal growth drivers for the company during this period. Revenue from these regions surged 64.9 percent year-on-year to ₹404.6 crore, propelled by organic business expansion and contributions from QliniQ B.V.\n\nThe US and North American markets also contributed significantly, with revenue growing 8.7 percent to ₹420.9 crore. This region remained the largest revenue contributor for Marksans Pharma, accounting for 44.8 percent of the company's total operating revenue.\n\nOn a regional level, Australia and New Zealand exhibited robust growth, with revenue increasing by 64 percent to ₹100.6 crore, driven by contributions from Nova Pharmaceuticals. However, revenue from the Rest of World segment witnessed a sharp decline of 47 percent to ₹14.1 crore, largely due to disruptions stemming from the ongoing West Asia crisis.\n\nThe quarterly results underscored Marksans Pharma's expanding international business presence, especially in Europe, Australia, and New Zealand. Despite challenges in certain overseas regions, the company managed to deliver higher revenue, improved operating margins, and stronger quarterly profitability, demonstrating resilience and growth potential.",
  "summary": "Mumbai: Marksans Pharma reported strong financial results for the second quarter of FY27, with net profit rising 44.8 per cent year-on-year to Rs 143.5 crore, compared with Rs 99.1 crore in the same quarter last year. The pharmaceutical company's operating revenue increased 30.5 per cent to Rs 940.2 crore from Rs 720.4 crore, crossing the Rs 900 crore milestone for the first time. Marksans Pharma…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}